MALVERN, Pa., April 27, 2015 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced additions to the executive team of William Stewart and Jessica Wolfe.
These appointments mark important steps in SCILEX's proprietary drug development program as it prepares for the potential commercialization of its products. The Company's first product, ZTlido™ (lidocaine patch 1.8%) is a next-generation patch being developed for the treatment of postherpetic neuralgia, also referred to as after-shingles pain.
"We are delighted to welcome Jessica and Bill to our team. Together, they have extensive industry expertise overseeing market access, commercialization, advocacy and government affairs programs," Anthony Mack, Chief Executive Officer of SCILEX said. "These attributes make them ideal candidates to help the Company as we advance ZTlido and explore other products for the treatment of pain."
Mr. Stewart has been named Vice President of Market Access and Commercial Development, joining SCILEX from InVentiv Health where he assisted emerging pharma companies in building the commercial infrastructure necessary for the launch of prescription pharmaceutical products. He has more than 30 years of experience, having won several national awards for his success in pharmaceutical sales, marketing and commercialization. Mr. Stewart has worked in leadership positions, overseeing the managed market access strategy at Novartis Pharmaceuticals and in sales management roles at Merck Pharmaceuticals. He earned a BS in Chemistry from the University of Arkansas and has completed financial and management courses at Wharton and Harvard.
Ms. Wolfe has been appointed Director of Payer Advocacy and Government Affairs, responsible for developing legislative, regulatory, payer and advocacy priorities. She brings more than a decade of experience, having worked for industry leaders such as Allergan, Cardinal Health and Medtronic in areas that include healthcare sales, reimbursement and lobbying. Ms. Wolfe joins the Company from InVentiv Health where she was Director of Advocacy and Government Affairs. Previously, she created Boston Scientific's first State Government Affairs Program, lobbying state-based healthcare legislation and public policy initiatives across the country. Ms. Wolfe holds a B.S. in political science and communication studies from Vanderbilt University, Tennessee.
About SCILEX Pharmaceuticals
SCILEX Pharmaceuticals, Inc., located in Malvern, PA, is an emerging specialty pharmaceutical company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain. The Company's vision is to become a world-class, global pharmaceutical company that delivers the next generation of innovative products. Leveraging its network of global relationships, the Company seeks to acquire high barrier-to-entry, late-stage products for development and commercialization. The Company's first product under development, ZTlido™ (lidocaine patch 1.8%), is a next-generation branded lidocaine patch formulation for the potential treatment of relieving the pain of postherpetic neuralgia, also referred to as after-shingles pain. For more information visit www.scilexpharma.com
ZTlido™ is a trademark owned by SCILEX Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners. A proprietary name review by the FDA is planned. © 2015 SCILEX Pharmaceuticals, Inc. All Rights Reserved.
For more information contact:
SCILEX Pharmaceuticals, Inc.
MBS Value Partners, LLC
SOURCE SCILEX Pharmaceuticals, Inc.